GRAIL, Inc. Common Stock (GRAL) Stock Price
GRALStock
$117.81+56.00%52W
Market Cap$5.26B
P/E—
PEG Ratio—
Div yield—
Beta1.88
GRAL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)135.33%
Price vs S&P 500 (4W)47.18%
VGM Score58.16
GRAL Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$2.43 | -$1.34 | +44.92%(+$1.09) | |
| Q1 2026 | -$1.96 | -$1.37 | +30.06%(+$0.59) | |
| Q4 2025 | -$2.53 | -$2.44 | +3.63%(+$0.09) | |
| Q3 2025 | -$3.27 | -$2.46 | +24.66%(+$0.81) | |
| Q2 2025 | -$3.56 | -$3.18 | +10.76%(+$0.38) |
GRAL Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.93
3.87
3.87
3.87
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
| CELCCelcuity Inc. Common Stock | — | — | D | — | — | — | -244.6% | $56.58 |
About GRAIL, Inc. Common Stock
GRAIL Inc develops a blood-based test for multi-cancer early detection designed to identify various cancer types at earlier stages. The company provides testing services focused on enabling earlier diagnosis and intervention, operating as a single business segment dedicated to cancer detection technology.